1990 2000 2004 6 2004 9 2004 10

  • Slides: 32
Download presentation

1990年代から始まる動き • 2000 • • • 2004. 6 2004. 9. 2004. 10 2004. 11

1990年代から始まる動き • 2000 • • • 2004. 6 2004. 9. 2004. 10 2004. 11 2005. 1 ヘルシンキ宣言改訂(エジンバラ) GSKの Paxil (paroxetine) scandal 医学雑誌編集者国際委員会(ICMJE) オタワ会議 オタワ声明 NY: WHO Int’l CT Registry Platform Meeting Mexico: Ministerial Summit on Health Res. 国際製薬 業協会(IFPMA) 声明 参考文献: 臨床医薬 2005; 21(1) 臨床試験登録・公開特集号 2

Statement of NY Workgroup (Oct. 2004) • Need for global approach to clinical trials

Statement of NY Workgroup (Oct. 2004) • Need for global approach to clinical trials registration – – – Unambiguous identification of trials Consensus needed on which trials; data; timing and disclosure of results One-stop search portal; publicly available System that is simple, effective, efficient Capacity built where appropriate • WHO should establish formal process toward a global approach – – Appropriate governance Collaborative process, involving all interested parties Existing structures leveraged; need for any new structures identified WHO mindful of ICMJE deadline 3

NY会議でまとめられた 10項目 1. Why register / disclose 2. Which trials to register 3. When

NY会議でまとめられた 10項目 1. Why register / disclose 2. Which trials to register 3. When to register 4. What data - Unique ID 5. What data – Trial descriptors 6. When to update 7. What to disclose at completion 8. Register characteristics 9. Ensuring compliance 10. Role for WHO 4 General agreement / Area requiring further discussion

6

6

Vickers A, et. al. Controlled Clinical Trials 1998; 19: 159 -66 7

Vickers A, et. al. Controlled Clinical Trials 1998; 19: 159 -66 7

Randomized Controlled Trial (RCT) sample 1, 000 R N D 500 reporting 1, 000

Randomized Controlled Trial (RCT) sample 1, 000 R N D 500 reporting 1, 000 random allocation interprelation random sampling statistical analysis population (generalizability) 10 IZ 65160 -10

ベルモントレポート(1979) 1. Respect for person 人の尊重 オートノミー 2. Beneficence 善行 3. Non-maleficence 無危害 4.

ベルモントレポート(1979) 1. Respect for person 人の尊重 オートノミー 2. Beneficence 善行 3. Non-maleficence 無危害 4. Justice 正義 12

Number of RCT/CCT/MA in Japan -prospective handsearch project- 津谷喜一郎. 臨床薬理 2003; 34(4): 210 -6

Number of RCT/CCT/MA in Japan -prospective handsearch project- 津谷喜一郎. 臨床薬理 2003; 34(4): 210 -6 15

Trends in Number of Chiken in Japan 16

Trends in Number of Chiken in Japan 16

Chiken (industry sponsored registration trials) is a part of clinical trials Clinical Trials Chiken

Chiken (industry sponsored registration trials) is a part of clinical trials Clinical Trials Chiken 17

Number of Clinical Trials in Japan in 2002 Clinical trials published n=1, 500 Chiken

Number of Clinical Trials in Japan in 2002 Clinical trials published n=1, 500 Chiken n=350 Review report to be publicized at PMDA web on approval 18 (PMDA: Pharmaceuticals and Medical Devices Agency)

Total number of clinical trials and its participants in Japan per year Number of

Total number of clinical trials and its participants in Japan per year Number of clinical trial Clinical trial (non-Chiken) Published RCT = 1, 000 Published non-RCT = ca 500 ? Unpublished CT = ? Chiken Registry to MHLW = 350 total = ca 2, 000 ? Number of trial participants 100 per trial x 2, 000 trials =200, 000 19

10. WHOの役割 • Provide facilitation standards developing area capacity • Avoid duplication bureaucracy Fund

10. WHOの役割 • Provide facilitation standards developing area capacity • Avoid duplication bureaucracy Fund ? 28

朝日新聞 2004. 7. 13 29

朝日新聞 2004. 7. 13 29